

	N (N=600)	%
Antibacterials		
<i>Extended spectrum beta-lactam antibiotics (piperacillin-tazobactam, ampicillin sulbactam, ticarcillin-clavulanate)</i>	283	47.2
<i>Vancomycin</i>	235	39.2
<i>Fluoroquinolones (Levoquin, Ciprofloxacin, Moxifloxacin, Gatifloxacin)</i>	160	26.7
<i>Cephalosporin (3rd or 4th generation)</i>	121	20.2
<i>Metronidazole</i>	53	8.8
<i>Carbapenems</i>	30	5.0
<i>Septa/Bactrim</i>	24	4.0
<i>Aminoglycosides</i>	19	3.2
<i>1st generation Cephalosporin</i>	13	2.2
<i>Astreonam</i>	9	1.5
<i>Doxycycline</i>	9	1.5
<i>Clindamycin</i>	8	1.3
<i>Ampicillin</i>	7	1.2
<i>Linezolid</i>	3	0.5
Antifungals		
<i>Fluconazole</i>	116	19.3
<i>Amphotericin B</i>	47	7.8
<i>Caspofungin/Micafungin</i>	11	1.8

Supplementary file #1. Table of antimicrobial and antifungal prophylaxis for 600 ALF patients.

Supplementary File #2
Prophylaxis, Death, and Blood Infection Rates by US ALFSG Site (Row Percentages).

	Prophylaxis		Dead		Blood Infection		Total	
	N	%	N	%	N	%	N	%
Total	600	38.7%	467	30.1%	226	14.6%	1551	100.0%
Center Number								
10	20/59	33.9%	29/59	49.2%	13/59	22.0%	59	100.0%
11	8	7.8%	34	33.3%	14	13.7%	102	100.0%
12	2	9.5%	6	28.6%	2	9.5%	21	100.0%
13	118	58.1%	41	20.2%	24	11.8%	203	100.0%
14	21	36.8%	20	35.1%	9	15.8%	57	100.0%
15	11	18.0%	20	32.8%	19	31.1%	61	100.0%
16	27	50.0%	10	18.5%	3	5.6%	54	100.0%
17	26	53.1%	20	40.8%	3	6.1%	49	100.0%
18	45	56.3%	23	28.8%	10	12.5%	80	100.0%
19	8	17.8%	17	37.8%	10	22.2%	45	100.0%
20	19	47.5%	15	37.5%	7	17.5%	40	100.0%
21	23	24.7%	21	22.6%	14	15.1%	93	100.0%
22	1	9.1%	3	27.3%	2	18.2%	11	100.0%
23	74	40.7%	59	32.4%	34	18.7%	182	100.0%
24	0	0.0%	0	0.0%	0	0.0%	4	100.0%
25	33	48.5%	27	39.7%	5	7.4%	68	100.0%
27	8	21.6%	10	27.0%	4	10.8%	37	100.0%
30	1	25.0%	0	0.0%	1	25.0%	4	100.0%
31	7	18.9%	6	16.2%	3	8.1%	37	100.0%
33	6	54.5%	3	27.3%	4	36.4%	11	100.0%
34	16	36.4%	11	25.0%	9	20.5%	44	100.0%
35	14	29.8%	16	34.0%	4	8.5%	47	100.0%
36	3	12.0%	7	28.0%	2	8.0%	25	100.0%
37	51	46.8%	41	37.6%	10	9.2%	109	100.0%
38	22	36.7%	17	28.3%	14	23.3%	60	100.0%
43	17	65.4%	3	11.5%	4	15.4%	26	100.0%
45	7	77.8%	6	66.7%	2	22.2%	9	100.0%
46	12	92.3%	2	15.4%	0	0.0%	13	100.0%

- Number of patients enrolled at that particular site who were placed on antimicrobial prophylaxis (and percentage)
 - E.g. 20/59 (33.9%) of patients at center 10 were placed on prophylactic antibiotics
- Number of patients deceased per enrolling site
 - e.g. 13/59 ~ 49.2% at site 10
- Number of patients with BSI per site (e.g. 13/59 ~ 22% at site 10)

URINE		Urine Infection (N=258)	No Urine Infection (N=1293)	p-value
Outcomes***				
	Liver Transplant	62 (24.0%)	311 (24.1%)	0.9941
	Alive at 21 days	184 (71.3%)	900 (69.6%)	0.5841

TRACHEAL/SPUTUM		Trach Infection (N=223)	No Trach Infection (N=1328)	p-value
Outcomes***				
	Liver Transplant	38 (17.0%)	335 (25.2%)	0.0081
	Alive at 21 days	154 (69.1%)	930 (70.0%)	0.7697

BLOODSTREAM		BSI (N=226)	No BSI (N=1325)	p-value
Outcomes***				
	Liver Transplant	43 (19.0%)	330 (24.9%)	0.06
	Alive at 21 days	134 (59.3%)	950 (71.7%)	0.0002

ANY INFECTION (Urine, Tracheal or blood)		Any Infection* (N=531)	No Infection (N=1020)	p-value
Outcomes***				
	Liver Transplant	120 (22.6%)	253 (24.8%)	0.3350
	Alive at 21 days	357 (67.2%)	727 (71.3%)	0.0996

Supplementary File #3. Transplant and 21-day survival status by site of infection

*Any infection is bloodstream, tracheal, or urine.

***21-day post-enrollment